Optic neuritis is a rare autoimmune disease characterized by the inflammation of the optic nerve. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...

Optic neuritis (ON) is an inflammation that damages your optic nerve. It can cause vision loss and pain when you move your eyes. As the inflammation goes away, your symptoms usually get better ...

Oculis Holding has reported that the randomised Phase II Acute OptiC NeUrITis of DemYelinating Origin (ACUITY) trial of OCS-05, in treating individuals with acute optic neuritis, met the primary ...

Optic neuritis needs prompt treatment, particularly when related to NMOSD and MOG, Lee said. A delay of even 4 days reduces the chance of regaining 20/20 vision by a factor of eight.

Oculis Holding AG. Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpo ...

The Phase 2 ACUITY (Acute OptiC NeUrITis of DemYelinating Origin) trial was a randomized, double-blind, placebo-controlled, multi-center trial, designed to evaluate OCS-05 (2mg/kg/day or 3mg/kg ...

The Phase 2 ACUITY (Acute OptiC NeUrITis of DemYelinating Origin) trial was a randomized, double-blind, placebo-controlled, multi-center trial, designed to evaluate OCS-05 (2mg/kg/day or 3mg/kg/day) ...

ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary ...